StockData
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Coherus Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.96−0.03 (-3.16%)

Close on Oct 19, 2026

Market cap
$148.42M
P/E (TTM)
0.7
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026During market hours$14.30M$-0.22$-0.19
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026During market hours$12.30M––
Q4 FY2025
Ended Dec 31, 2025
Mar 9, 2026During market hours$12.70M$-0.39$-0.34
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025During market hours$11.60M$-0.38$-0.33
Q2 FY2025
Ended Jun 30, 2025
Aug 7, 2025During market hours$10.30M$-0.39$-0.34
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025During market hours$7.60M–$-0.35
Q4 FY2024
Ended Dec 31, 2024
Mar 10, 2025During market hours–$-0.44$-0.28
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024During market hours$70.80M$-0.09$-0.01
Q2 FY2024
Ended Jun 30, 2024
Aug 8, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
May 9, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Mar 13, 2024During market hours–––

Company guidance

Outlook given with results on Jan 13, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Revenuesby 2028$150.00M to $200.00MNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Coherus Oncology filed with the SEC